Search

Your search keyword '"Martínez-Valbuena, Iván"' showing total 14 results
Start Over Author "Martínez-Valbuena, Iván"
14 results on '"Martínez-Valbuena, Iván"'

2. Nanobiotechnology in Parkinson’s Disease

Author

Torres-Ortega, Pablo Vicente, Martínez-Valbuena, Iván, Martí-Andrés, Gloria, Hanafy, Amira Sayed, Luquin, María Rosario, Garbayo, Elisa, Blanco-Prieto, María José, Rai, Mahendra, editor, and Yadav, Alka, editor

Published
2019
Full Text
View/download PDF

13. Small fiber neuropathy and phosphorylated alpha-synuclein in the skin of E46K- SNCA mutation carriers

Author

Neurociencias, Neurozientziak, Carmona Abellán, Mar, Gabilondo Cuellar, Iñigo, Murueta-Goyena Larrañaga, Ane, Khurana, Vikhram, Tijero Merino, Beatriz, Luquín, María Rosario, Acera, Marian, Del Pino Sáez, Rocío, Gardeazabal García, Jesús, Martínez-Valbuena, Iván, Sánchez-Pernaute, Rosario, Gómez Esteban, Juan Carlos, Neurociencias, Neurozientziak, Carmona Abellán, Mar, Gabilondo Cuellar, Iñigo, Murueta-Goyena Larrañaga, Ane, Khurana, Vikhram, Tijero Merino, Beatriz, Luquín, María Rosario, Acera, Marian, Del Pino Sáez, Rocío, Gardeazabal García, Jesús, Martínez-Valbuena, Iván, Sánchez-Pernaute, Rosario, and Gómez Esteban, Juan Carlos

Abstract

Background and objective: In 2004 we described the E46K mutation in alpha-synuclein gene (E46K-SNCA), a rare point mutation causing an aggressive Lewy body disease with early prominent non-motor features and small fiber denervation of myocardium. Considering the potential interest of the skin as a target for the development of biomarkers in Parkinson's Disease (PD), in this work we aimed to evaluate structural and functional integrity of small autonomic nerve fibers and phosphorylated alpha-synuclein (p-synuclein) deposition in the skin of E46K- SNCA carriers as compared to those observed in parkin gene mutation (PARK2) carriers and healthy controls. Patients and methods: We studied 7 E46K-SNCA carriers (3 dementia with Lewy bodies, 2 pure autonomic failure, 1 PD and 1 asymptomatic), 2 PARK2 carriers and 2 healthy controls to quantify intraepidermal nerve fiber density and p-synuclein deposition with cervical skin punch biopsies (immunohistochemistry against anti PGP9.5/UCHL-1, TH and p-synuclein) and sudomotor function with electrochemical skin conductance (ESC) (SudoScan). Results: All E46K-SNCA carriers had moderate to severe p-synuclein deposits and small fiber neurodegeneration in different epidermal and dermal structures including nerve fascicles and glands, especially in carriers with Pure Autonomic Failure, while p-synuclein aggregates where absent in healthy controls and in one of two PARK2 carriers. The severity of the latter skin abnormalities in E46K-SNCA were correlated with sudomotor dysfunction (lower ESC) in hands (p = 0.035). Interpretation: These results together with our previous findings support the relevance of E46K-SNCA mutation as a suitable model to study small fiber neuropathy in Lewy body diseases.

Published
2019

14. Interictal amylin levels in chronic migraine patients: A case-control study.

Author

Irimia, Pablo, Martínez-Valbuena, Iván, Mínguez-Olaondo, Ane, Domínguez-Vivero, Clara, Sánchez-Arias, Juan-Antonio, Martínez-Vila, Eduardo, Luquin, María-Rosario, and Leira, Rogelio

Subjects
*AMYLIN, *CALCITONIN gene-related peptide, *MIGRAINE, *CLUSTER headache, *BODY mass index, *CASE-control method
Abstract

Background: Recently, amylin and its receptors were found in different structures involved in migraine pathophysiology. Here, we evaluate interictal concentrations of amylin and calcitonin gene-related peptide in peripheral blood as biomarkers for chronic migraine. Methods: We prospectively recruited patients with episodic migraine, chronic migraine and healthy controls. Interictal amylin and calcitonin gene-related peptide levels were assessed in blood samples using enzyme linked immunosorbent assay. Results: We assessed plasma samples from 58 patients with episodic migraine (mean age 37.71 ± 10.47, 87.9% female), 191 with chronic migraine (mean age 46.03 ± 11.93, 95% female), and on 68 healthy controls (mean age 43.58 ± 11.08 years, 86% female). Body mass index was 25.94 ± 4.53 kg/m2 for migraine patients and 25.13 ± 4.92 kg/m2 for healthy controls (p = 0.0683). Interictal plasma amylin levels were higher in chronic migraine patients (47.1 pg/mL) than in the episodic migraine patients (28.84 pg/mL, p < 0.0001) and healthy controls (24.74 pg/mL, p < 0.0001). Plasma calcitonin gene-related peptide levels were increased (20.01 pg/mL) in chronic migraine patients when compared to healthy controls (11.37 pg/mL, p = 0.0016), but not to episodic migraine patients (18.89 pg/mL, p = 0.4369). Applying a cut-off concentration of 39.68 pg/mL plasma amylin, the sensitivity to differentiate chronic migraine from healthy controls was 57.6% and the specificity was 88.2%. Variables such as age, analgesic overuse, depression, allodynia, use of preventive medication or a history of aura did not influence the plasma concentrations of amylin or calcitonin gene-related peptide. Conclusion: Interictal plasma amylin levels are higher in patients with chronic migraine and may serve as a diagnostic biomarker for chronic migraine. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results